Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report by State

Non-Hodgkin Lymphoma (All Stages^), 2018-2022

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by CI*Rank

Explanation of Column Headers
Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Recent Trends - This is an interpretation of the AAPC/APC:

AAPC/APC (95% Confidence Interval) - the change in rate over time


Other Notes


Line by Line Interpretation of the Report


Minnesota2


Florida2


Iowa7


Connecticut7


New Jersey7


Wisconsin2


New York7


New Hampshire2


Kentucky7


Maine2


West Virginia2


Vermont2


Washington1


Missouri2


Ohio2


South Dakota2


Pennsylvania2


Kansas2


Louisiana7


Illinois7


Idaho7


Nebraska2


North Dakota2


Michigan2


Rhode Island2


Utah7


Massachusetts2


Alaska2


Indiana2


California7


North Carolina2


Arkansas2


Oregon2


Texas7


Delaware2


Montana2


Oklahoma2


Maryland2


Georgia7


Tennessee2


Colorado2


Virginia2


Mississippi2


Wyoming2


South Carolina2


District of Columbia2


Arizona2


Hawaii7


Nevada2


Alabama2


New Mexico7


Puerto Rico2





Notes:
Created by statecancerprofiles.cancer.gov on 03/21/2026 6:30 pm.

State Cancer Registries may provide more current or more local data.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates and trends are computed using different standards for malignancy. For more information see malignant.html.

^ All Stages refers to any stage. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

Source: SEER and NPCR data. For more specific information please see the table.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.